LINC00880: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

Target Name: LINC00880

NCBI ID: G339894

LINC00880

Other Name(s): Long intergenic non-protein coding RNA 880 | long intergenic non-protein coding RNA 880

LINC00880: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

LINC00880 is a long non-protein-coding RNA (lncRNA) that has been identified in various organisms, including humans. It has a unique feature of being located between the genes, which results in its name. LINC00880 has been shown to play a crucial role in various cellular processes, and its levels have been linked to various diseases. Therefore, it may be a potential drug target or biomarker.

Drug Target

LINC00880 has been shown to be involved in the regulation of cell adhesion, which is an essential process that plays a vital role in tissue repair and regeneration. The intercellular adhesion molecule (IcAM) is a protein that is known to interact with LINC00880. This interaction may be a potential target for drugs that aim to treat diseases that are characterized by disrupted cell adhesion.

For example, studies have shown that LINC00880 is downregulated in various types of cancer, including breast, ovarian, and colorectal cancer. Additionally, overexpression of LINC00880 has been shown to promote the growth and metastasis of these cancers. Therefore, targeting LINC00880 may be a promising strategy for the development of new cancer therapies.

Biomarker

LINC00880 has also been shown to be involved in the regulation of cell cycle progression. The cell cycle is the process by which cells grow, divide, and replicate their genetic material. LINC00880 has been shown to regulate the length of the S-phase, which is a critical stage in the cell cycle where DNA replication occurs.

Furthermore, LINC00880 has been shown to play a role in the regulation of mitosis, which is the process by which a cell divides. Overexpression of LINC00880 has been shown to increase the number of mitosis and promote the formation of multi-copy copies of genomic DNA. This may contribute to the development of cancer.

Additionally, LINC00880 has been shown to play a role in the regulation of angiogenesis, which is the process by which new blood vessels are formed. Overexpression of LINC00880 has been shown to promote the growth and formation of new blood vessels in various organs, including the liver and the kidneys. This may contribute to the development of diseases characterized by impaired angiogenesis, such as heart failure and ischemia.

Conclusion

In conclusion, LINC00880 is a long non-protein-coding RNA that has been shown to play a crucial role in various cellular processes. Its levels have been linked to various diseases, including cancer and Angiogenesis. Therefore, LINC00880 may be a potential drug target or biomarker. Further studies are needed to fully understand the role of LINC00880 in various biological processes and to explore its potential as a drug or biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 880

The "LINC00880 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00880 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets